Research and Markets: Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development
Posted on: Wednesday, 31 August 2005, 12:00 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c23512) has announced the addition of Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development to their offering
Molecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development.
This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer. Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns.
For more information visit http://www.researchandmarkets.com/reports/c23512
Source: Business Wire
Related Articles
- SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
- Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference
- New Molecular Pathway For Targeting Cancer, Disease
- 2009 Medical Innovation Summit at Cleveland Clinic to Highlight the Latest Developments in Cancer Care
- Myriad Genetics to Spin Off Drug Development Business
- Curis Selects First Development Candidate From Its Targeted Cancer Drug Development Platform
- HIV Drug Stops Cervical Cancer in Laboratory Test
- Idera Pharmaceuticals Announces Formation of Oncology Clinical Advisory Board; Accomplished Physicians and Scientists in Cancer Drug Development
- Callisto Pharmaceuticals Receives Investment Recommendation From Independent European Stock Newsletter; Strong Buy Investor Newsletter Cites Company's Drug Development Pipeline and Clinical Progress of Atiprimod and L-Annamycin
- Target Discovery and Eastern Virginia Medical School Announce Collaboration to Develop Prostate Cancer Clinical Assays
 |
 |
User Comments (0)
RSS Feeds